ZVRA Estatísticas principais
Alta
9.99
Abrir
9.53
Volume
1.51M
Baixa
9.47
Fechamento anterior
9.53
Valor negociado
14.76M
52 sem. máx.
15.04
Vol. relativo
0.961
Amplitude (%)
5.46%
52 sem. mín.
7.16
Taxa de giro
2.57%
Cap. de Mercado
563.07M
P/L (TTM)
4.42
P/L (Anual)
6.807
P/VP
2.74
P/S
4.61
Lucro por ação (EPS)
2.154
Dividendo (TTM)
0
Rendimento de dividendos
0.00%
Ações em circulação
59.11M
Unidade monetária
USD
ZVRA Desempenho de Preço
7 dia
30 dia
90 dia
180 dia
No acumulado do ano
1 Ano
ZVRA Distribuição do fluxo de dinheiro
ZVRA Volume diário de venda a descoberto
ZVRA Histórico de short interest
ZVRA Visão geral da ação
As of 2026-07-27, the Zevra Therapeutics, Inc. (ZVRA) stock price today is 9.71. Based on this price, the company has a market capitalization of $563.07M, with a P/E ratio of 4.42.
On 2026-07-27, ZVRA traded between 9.47 and 9.99. Today’s stock price is 2.53% above the daily low and 2.80% below the daily high, placing ZVRA perto do meio de its most recent trading range.
Trading volume currently stands at 1.51M, compared with an average daily volume of 1.58M. This suggests that trading activity is aproximadamente em linha com o nível habitual than usual.
Over the past year, Zevra Therapeutics, Inc. shares have traded between 7.16 and 15.04. At today’s price, ZVRA is 35.61% above its 52-week low and 35.44% below its 52-week high.
ZVRA Notícias relacionadas
Sobre ZVRA
Nome empresa
Zevra Therapeutics, Inc.
Setor
Health Technology
Indústria
Pharmaceuticals: Major
Trocas
Nasdaq
Número de funcionários
61
Tamanho do lote
100
Site oficial
Unidade monetária
USD
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
Related Stocks
ZVRA FAQ
© 2026 CoinGlass, all rights reserved
